Skip to main content
PUMA BIOTECHNOLOGY, INC. logo

PUMA BIOTECHNOLOGY, INC. — Investor Relations & Filings

Ticker · PBYI ISIN · US74587V1070 US Manufacturing
Filings indexed 1,055 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country US United States of America
Listing US PBYI

About PUMA BIOTECHNOLOGY, INC.

https://www.pumabiotechnology.com/

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. The company's primary commercial product is Nerlynx® (neratinib), an FDA-approved oral medication for certain types of breast cancer. Its clinical pipeline includes alisertib, an investigational drug being evaluated in clinical trials for small cell lung cancer and metastatic breast cancer. The company's mission is to develop and commercialize innovative products to enhance cancer care.

Recent filings

Filing Released Lang Actions
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Regulatory Filings
2026-05-07 English
ARS - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Annual Report
2026-04-28 English
SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
Major Shareholding Notification
2026-03-27 English
10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Regulatory Filings
2026-02-26 English
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Director's Dealing
2026-02-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.